secwatch.observer — SEC 8-K summary
======================================

Issuer:     PROTHENA CORP PUBLIC LTD CO (PRTA)
CIK:        0001559053
Form:       8-K
Filed at:   2024-01-08T23:59:59+00:00
Accession:  0001193125-24-003972
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Prothena reports $621M cash at year-end 2023; pipeline updates on PRX012, PRX123, birtamimab
--------------------------------------------------------------------------------

- Cash, cash equivalents, and restricted cash ~$621M as of Dec 31, 2023; sufficient capital beyond ongoing trials.
- PRX012 (Alzheimer's): Phase 1 data supports once-monthly dosing; dose escalation to 200-400mg underway.
- PRX123 (Alzheimer's vaccine): IND cleared and Fast Track designation; Phase 1 timeline update expected in 2024.
- Birtamimab (AL amyloidosis): Phase 3 AFFIRM-AL enrollment on track; topline results expected 4Q24-2Q25.
- Partnered programs with BMS, Roche, Novo Nordisk remain on track; BMS-986446 moving to Phase 2 in 1H24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1559053/000119312524003972/0001193125-24-003972-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1559053/000119312524003972/d707357d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-24-003972

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer